To determine if targeting the endogenous inhibitor of CatB, CSTB, might be a viable strategy to increase cathepsin B activity in the context of trisomy of Hsa21, we used a siRNA approach to reduce CSTB abundance in human fibroblasts isolated from individuals with DS and matched euploid controls. This evidence concerns the gene TYRP1 and Dravet syndrome.